BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?

Nearly four decades after their conceptualization, antibody-based therapies are slowly being added to the treatment landscape of acute myeloid leukemia (AML). While the antibody–drug conjugate gemtuzumab ozogamicin is the only antibody-based therapy that has been approved for AML treatment thus far,...

Descripción completa

Detalles Bibliográficos
Autores principales: Allen, Cecily, Zeidan, Amer M., Bewersdorf, Jan Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224808/
https://www.ncbi.nlm.nih.gov/pubmed/34071099
http://dx.doi.org/10.3390/life11060465

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224808/
https://www.ncbi.nlm.nih.gov/pubmed/34071099
http://dx.doi.org/10.3390/life11060465

Ejemplares similares